The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARβ2 in colon cancer cells

Nutrition and Cancer

Volumn 60, Issue 5, 2008, Pages 692-702

  Spurling, Colleen C ^a   Suhl, Joshua A ^a   Boucher, Nathalie ^a   Nelson, Craig E ^a   Rosenberg, Daniel W ^b   Giardina, Charles ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID; DNA METHYLTRANSFERASE INHIBITOR; GENISTEIN; HISTONE DEACETYLASE 1; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; SHORT CHAIN FATTY ACID;

ARTICLE; CANCER CELL; CANCER PREVENTION; COLON CANCER; DEMETHYLATION; DIETARY FIBER; DNA REPLICATION; ENZYME INHIBITION; EPIGENETICS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE;

BLOTTING, WESTERN; BUTYRATES; CELL CULTURE TECHNIQUES; COLONIC NEOPLASMS; DNA METHYLATION; HUMANS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID;

EID: 51849099492     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802008278     Document Type: Article

References (70)

1. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26, 5420-5432, 2007.
2. Mann BS, Johnson JR, Cohen MH, Justice R, and Pazdur R: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247-1252, 2007.
3. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25, 3109-3115, 2007.
4. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, et al.: Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13, 2318-2322, 2007.
5. Camphausen K and Tofilon PJ: Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 25, 4051-4056, 2007.
6. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, et al.: Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13, 4538-4546, 2007.
7. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, et al.: Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6, 70-81, 2007.
8. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, et al.: Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20, 1860-1872, 2001.
9. Boivin AJ, Momparler LF, Hurtubise A, and Momparler RL: Antineoplastic action of 5-aza-2-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13, 869-874, 2002.
10. Gagnon J, Shaker S, Primeau M, Hurtubise A, and Momparler RL: Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14, 193-202, 2003.
11. Camphausen K, Scott T, Sproull M, and Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10, 6066-6071, 2004.
12. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, and Harari PM: Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62, 223-229, 2005.
13. Pei XY, Dai Y, and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10, 3839-3852, 2004.
14. Dashwood RH, Myzak MC, and Ho E: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27, 344-349, 2006.
15. Myzak MC, Dashwood WM, Orner GA, Ho E, and Dashwood RH: Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J 20, 506-508, 2006.
16. Hinnebusch BF, Meng S, Wu JT, Archer SY, and Hodin RA: The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132, 1012-1017, 2002.
17. Boffa LC, Lupton JR, Mariani MR, Ceppi M, Newmark HL, et al.: Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 52, 5906-5912, 1992.
18. Sealy L and Chalkley R: The effect of sodium butyrate on histone modification. Cell 14, 115-121, 1978.
19. Heerdt BG, Houston MA, and Augenlicht LH: Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54, 3288-3293, 1994.
20. Mariadason JM, Corner GA, and Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60, 4561-4572, 2000.
21. Augenlicht LH, Mariadason JM, Wilson A, Arango D, Yang W, et al.: Short chain fatty acids and colon cancer. J Nutr 132, 3804S-3808S, 2002.
22. Augeron C and Laboisse CL: Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 44, 3961-3969, 1984.
23. Gonzalez CA: The European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 9, 124-126, 2006.
24. Lanza E, Schatzkin A, Daston C, Corle D, Freedman L, et al.: Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. Am J Clin Nutr 74, 387-401, 2001.
25. Lanza E, Yu B, Murphy G, Albert PS, Caan B, et al.: The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 16, 1745-1752, 2007.
26. Meyskens FL Jr and Szabo E: Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 14, 1366-1369, 2005.
27. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134, 3479S-3485S, 2004.
28. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al.: Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res 67, 836-843, 2007.
29. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, et al.: Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. J Nutr 137, 2443-2450, 2007.
30. Hong MY, Chapkin RS, Barhoumi R, Burghardt RC, Turner ND, et al.: Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis 23, 1919-1925, 2002.
31. Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, et al.: The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 26, 1914-1921, 2005.
32. Mistry AR, Pedersen EW, Solomon E, and Grimwade D: The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 17, 71-97, 2003.
33. Higuchi E, Chandraratna RA, Hong WK, and Lotan R: Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22, 4627-4635, 2003.
34. Lippman SM, Benner SE, and Hong WK: Retinoids in chemoprevention of head and neck carcinogenesis. Prev Med 22, 693-700, 1993.
35. Youssef EM, Estecio MR, and Issa JP: Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther 3, 82-86, 2004.
36. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, et al.: Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11, 7033-7041, 2005.
37. Aizu W, Belinsky GS, Flynn C, Noonan EJ, Boes CC, et al.: Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors. Biochem Pharmacol 72, 981-991, 2006.
38. Si J and Collins SJ: IL-3-induced enhancement of retinoic acid receptor activity is mediated through Stat5, which physically associates with retinoic acid receptors in an IL-3-dependent manner. Blood 100, 4401-4409, 2002.
39. Tong X, Yin L, Joshi S, Rosenberg DW, and Giardina C: Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors. J Biol Chem 280, 15503-15509, 2005.
40. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427-1431, 2002.
41. Frigola J, Ribas M, Risques RA, and Peinado MA: Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res 30, e28, 2002.
42. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, et al.: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 7563-7570, 2003.
43. Myzak MC and Dashwood RH: Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 7, 443-452, 2006.
44. Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, et al.: Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol 40, 556-562, 1991.
45. Bernard BA, Bernardon JM, Delescluse C, Martin B, Lenoir MC, et al.: Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun 186, 977-983, 1992.
46. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45, 495-528, 2005.
47. Goldberg AD, Allis CD, and Bernstein E: Epigenetics: a landscape takes shape. Cell 128, 635-638, 2007.
48. Szyf M: Therapeutic implications of DNA methylation. Future Oncol 1, 125-135, 2005.
49. Toyota M and Issa JP: Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32, 521-530, 2005.
50. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1, R50-59, 2007.
51. Fraga MF, Agrelo R, and Esteller M: Cross-talk between aging and cancer: the epigenetic language. Ann NY Acad Sci 1100, 60-74, 2007.
52. Ekbom A, Helmick C, Zack M, and Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323, 1228-1233, 1990.
53. Issa JP, Ahuja N, Toyota M, Bronner MP, and Brentnall TA: Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61, 3573-3577, 2001.
54. Fang M, Chen D, and Yang CS: Dietary polyphenols may affect DNA methylation. J Nutr 137, 223S-228S, 2007.
55. Schroder O, Turak S, Daniel C, Gaschott T, and Stein J: Upregulation of 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase by butyrate in Caco-2 cells. World J Gastroenterol 11, 7136-7141, 2005.
56. Milutinovic S, D'Alessio AC, Detich N, and Szyf M: Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 28, 560-571, 2007.
57. Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, et al.: Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 73, 1297-1307, 2007.
58. Dong E, Guidotti A, Grayson DR, and Costa E: Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA 104, 4676-4681, 2007.
59. Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, et al.: Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11, 3535-3542, 2005.
60. Bhattacharya SK, Ramchandani S, Cervoni N, and Szyf M: A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397, 579-583, 1999.
61. Cedar H and Verdine GL: Gene expression: the amazing demethylase. Nature 397, 568-569, 1999.
62. Wolffe AP, Jones PL, and Wade PA: DNA demethylation. Proc Natl Acad Sci USA 96, 5894-5896, 1999.
63. Smith SS: Gilbert's conjecture: the search for DNA (cytosine-5) demethylases and the emergence of new functions for eukaryotic DNA (cytosine-5) methyltransferases. J Mol Biol 302, 1-7, 2000.
64. Gjerset RA and Martin DWJr: Presence of a DNA demethylating activity in the nucleus of murine erythroleukemic cells. J Biol Chem257, 8581-8583, 1982.
65. Razin A, Szyf M, Kafri T, Roll M, Giloh H, et al.: Replacement of 5-methylcytosine by cytosine: a possible mechanism for transient DNA demethylation during differentiation. Proc Natl Acad Sci USA 83, 2827-2831, 1986.
66. Ramchandani S, Bhattacharya SK, Cervoni N, and Szyf M: DNA methylation is a reversible biological signal. Proc Natl Acad Sci USA 96, 6107-6112, 1999.
67. Hendrich B, Hardeland U, Ng HH, Jiricny J, and Bird A: The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401, 301-304, 1999.
68. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, et al.: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082, 2002.
69. Kim YI: Folate: a magic bullet or a double edged sword for colorectal cancer prevention? Gut 55, 1387-1389, 2006.
70. Kim YI: Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 135, 2703-2709, 2005.